hVIVO (LON:HVO) Stock Price Down 46.3% - Here's What Happened

hVIVO plc (LON:HVO - Get Free Report) was down 46.3% during mid-day trading on Friday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). Approximately 83,062,008 shares changed hands during trading, an increase of 2,325% from the average daily volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).

Wall Street Analyst Weigh In

Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a report on Friday.

hVIVO Stock Performance

The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The stock has a fifty day moving average of GBX 16.16 and a 200-day moving average of GBX 18.04. The stock has a market cap of £61.56 million, a PE ratio of 3.59 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last released its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, equities analysts forecast that hVIVO plc will post 1.5492958 EPS for the current year.

Insider Buying and Selling

In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of hVIVO stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,648.48). Corporate insiders own 14.03% of the company's stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.